It’s Time to
Build in Bio
Our ability to engineer biology is fundamentally transforming how we diagnose, treat, and manage disease. Modern tools like CRISPR and gene circuitry enable us to program biology with greater precision and sophistication. The explosion of “programmable medicines” (in the form of genes, cells, microbes, and even mobile apps and software that can improve our health itself) are today leading us closer than ever before to that holy grail of medicine, the cure.
Because these new medicines are engineered systems and programmable in nature, drug discovery and development is becoming an engineered, iterative process. We can now move from designing a molecule for one specific target to designing a platform on which many future medicines can be built. And the modular aspect of these medicines mean that new applications will be easier to build, reusing and repurposing common components like Lego blocks: Once we learn how to deliver a gene to a specific cell in a given disease, it’s significantly more likely we will be able to deliver a different gene to a different cell for another disease.
Biology is incredibly complex —maybe even beyond the ability of the human mind to fully comprehend. AI-powered platforms have the potential to connect dots that have before looked like noise; to generate new discoveries; even to change the nature of discovery itself. This will drive both new therapies and next-generation diagnostics that give us the ability to detect diseases like cancer earlier and earlier, perhaps even stopping disease before it begins..
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. Exits include current and former a16z portfolio companies which have been acquired as well as companies which have undergone an initial public offering or direct public offering of shares. Certain publicly traded companies on this list may still be held in Andreessen Horowitz funds. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Excluded from this list are investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets. Further, the list of investments is updated monthly and as such may not reflect most recent a16z investments. Past results of Andreessen Horowitz’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results.
Themes in Bio
Science-native SaaS tools are modernizing how medicines are discovered, developed, and distributed.
Our top-ranked podcast exploring the real challenges and enormous opportunities facing entrepreneurs who are building the future of health.
Building in Bio
A new generation of founders is building a new generation of bio companies.
Journal Club: Remodeling oncogenic transcriptomes
Unexpected results and translational implications from a recent paper, in one of our Journal Club podcast episodes.
AI in Bio + Health
A universe of new therapies, next-gen diagnostics, and provider tools is on the horizon.
the Field of Immunotherapies
Immuno-oncology and current challenges in drug targeting, explained.
AI and Actionable Drug Insights with Daphne Koller
Hear about how AI can enable new models of discovery in biology, in this episode of Bio Eats World.
Scribe Therapeutics cofounder and CEO Ben Oakes joins a16z Bio + Health founding general partner Vijay Pande.
The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. But how can biotech teams effectively communicate to investors and partners how they will, with each round of financing, incrementally reduce the risks of discovering and developing successful new drugs?
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.
Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.